Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4454568 | 0.83 | USP2 (0.41) | USP2SMN1; SMN2EPHX2EPHX1NR1H2 | |
| SCHEMBL31481322 | 0.81 | USP2 (0.42) | USP2SMN1; SMN2EPHX2EPHX1NR1H2 | |
| SCHEMBL34474707 | 0.80 | USP2 (0.41) | USP2SMN1; SMN2EPHX2EPHX1NR1H2 | |
| SCHEMBL27299852 | 0.79 | USP2 (0.46) | USP2SMN1; SMN2EPHX2EPHX1NR1H2 | |
| SCHEMBL27100470 | 0.78 | USP2 (0.42) | USP2SMN1; SMN2EPHX2EPHX1 | |
| SCHEMBL34473673 | 0.77 | USP2 (0.44) | USP2SMN1; SMN2EPHX2EPHX1NR1H2 | |
| SCHEMBL30713621 | 0.75 | EPHX2 (0.40) | USP2SMN1; SMN2EPHX2EPHX1NR1H2 | |
| SCHEMBL1394450 | 0.74 | USP2 (0.52) | USP2SMN1; SMN2EPHX2EPHX1NR1H2 | |
| SCHEMBL13607132 | 0.73 | USP2 (0.41) | USP2SMN1; SMN2EPHX2EPHX1NR1H2 | |
| SCHEMBL27390358 | 0.73 | USP2 (0.41) | USP2SMN1; SMN2EPHX2EPHX1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632840-B2 | Quinazoline compounds for the treatment of hyperproliferative disorders | ASTRAZENECA AB (SE) | 2009-12-15 | — | — | US | disclosed |
| EP-1713781-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| US-20070293490-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| US-20070293490-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| EP-1713781-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005075439-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293490-A1 | Quinazoline Derivatives | CCNA1, CCND3, CCND2 | USP2 3959/4885SMN1; SMN2 4529/4885EPHX2 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.